In this Phase 3 trial, 108 patients with ALS carrying SOD1 mutations were randomized at a 2:1 ratio to receive either 100 mg tofersen or placebo, administered intrathecally for a total of eight doses over 24 weeks. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.